Literature DB >> 21414656

Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer.

Philipp Harter1, Zelal M Muallem, Christine Buhrmann, Dietmar Lorenz, Christine Kaub, Rita Hils, Stefan Kommoss, Florian Heitz, Alexander Traut, Andreas du Bois.   

Abstract

OBJECTIVE: Surgical outcome in advanced ovarian cancer (AOC) is an important prognostic factor and the only factor amendable to improvement by optimization. Therefore, introduction of quality management programs (QM) regarding the surgical therapy in ovarian cancer may help to improve outcome.
METHODS: We introduced a specific ovarian cancer quality management program in 2001 in our gynecologic oncology center. Analysis of 396 consecutive patients with primary surgery for advanced ovarian cancer FIGO stages IIB-IV operated before the introduction of the quality management program 1997-2000, or during the introduction years 2001-2003, or after establishing 2004-2008.
RESULTS: Thirty-three percent had complete debulking to no macroscopic residual disease from 1997 to 2000. This rate increased to 47% in 2001-2003 (n = 86) and 62% in 2004-2008 (n = 259). The utilization of extended surgical procedures increased over time. Patients with complete resection had 5-YSR of 55% compared to 16% in patients with residuals 1-10 mm, and 13% in patients with residuals >1 cm (p < 0.001). The median OS increased from 26 months 1997-2000 to 37 months 2001-2003 and 45 months in 2004-2008 (p < 0.003).
CONCLUSIONS: Optimizing surgical skills, infrastructure, and introduction of quality management programs may improve both surgical and overall outcome in advanced ovarian cancer.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21414656     DOI: 10.1016/j.ygyno.2011.02.014

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  39 in total

1.  MiR-143 targets CTGF and exerts tumor-suppressing functions in epithelial ovarian cancer.

Authors:  Lufei Wang; Jin He; Hongmei Xu; Longjie Xu; Na Li
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

2.  Prognostic value of preoperative intratumoral FDG uptake heterogeneity in patients with epithelial ovarian cancer.

Authors:  Maria Lee; Hyunjong Lee; Gi Jeong Cheon; Hee Seung Kim; Hyun Hoon Chung; Jae-Weon Kim; Noh-Hyun Park; Yong Sang Song
Journal:  Eur Radiol       Date:  2016-04-27       Impact factor: 5.315

3.  Quality Indicators and Survival Outcome in Stage IIIB-IVB Epithelial Ovarian Cancer Treated at a Single Institution.

Authors:  Inga Steinberga; Kjell Jansson; Bengt Sorbe
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

Review 4.  Novel Surgical Strategies in the Treatment of Gynecological Malignancies.

Authors:  Martina Aida Angeles; Carlos Martínez-Gómez; Federico Migliorelli; Marie Voglimacci; Justine Figurelli; Stephanie Motton; Yann Tanguy Le Gac; Gwénaël Ferron; Alejandra Martinez
Journal:  Curr Treat Options Oncol       Date:  2018-11-09

5.  Observed-to-expected ratio for adherence to treatment guidelines as a quality of care indicator for ovarian cancer.

Authors:  Valerie B Galvan-Turner; Jenny Chang; Argyrios Ziogas; Robert E Bristow
Journal:  Gynecol Oncol       Date:  2015-09-24       Impact factor: 5.482

6.  Sexual Function, Sexual Activity and Quality of Life in Women with Ovarian and Endometrial Cancer.

Authors:  P Harter; I Schrof; L M Karl; R Hils; V Kullmann; A Traut; H Scheller; A du Bois
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-05       Impact factor: 2.915

7.  Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer.

Authors:  P Harter; S Mahner; F Hilpert; I Runnebaum; O Ortmann; A Mustea; J Sehouli; A du Bois; U Wagner
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-03       Impact factor: 2.915

8.  Less guessing, more evidence in identifying patients least fit for cytoreductive surgery in advanced ovarian cancer: A triage algorithm to individualize surgical management.

Authors:  Deepa Maheswari Narasimhulu; Amanika Kumar; Amy L Weaver; Carrie L Langstraat; William A Cliby
Journal:  Gynecol Oncol       Date:  2020-04-01       Impact factor: 5.482

9.  Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.

Authors:  Ying Shen; Li Li
Journal:  Tumour Biol       Date:  2016-09-15

10.  Advanced ovarian cancer: what should be the standard of care?

Authors:  Barbara A Goff
Journal:  J Gynecol Oncol       Date:  2013-01-08       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.